The largest evidence base in digital mental health
Daylight helped 71% of participants move from clinical to sub-clinical levels of worry & anxiety
By week 10 follow-up, 71% of Daylight users in the study moved from clinical to sub-clinical levels of worry & anxiety, as compared to 33% of those in the control group. Improvements were maintained at week 26 (uncontrolled) follow-up.
Disclaimer: In the US, Sleepio and Daylight have not been cleared by the FDA for use in diagnosis or treatment of a disease or condition, such as insomnia disorder, generalized anxiety disorder, or major depressive disorder. Users are directed to not make any changes to their prescribed medication or other type of medical treatment without seeking professional medical advice.